Aminocaproic acid (Aminocaproic acid)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAminocaproic acidAminocaproic acid
Similar drugsTo uncover
  • Aminocaproic acid
    solution d / infusion 
    ALIUM PFK, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
    PLANT MEDSINTEZ, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    Promomed Rus, Open Company     Russia
  • Aminocaproic acid
    solution d / infusion 
    NESVIZH FACTORY OF MEDICAL PREPARATIONS, RUP     Republic of Belarus
  • Aminocaproic acid
    solution d / infusion 
    FIRM MEDPOLIMER, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    MOSFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    Avexima Sibir, OOO     Russia
  • Aminocaproic acid-SOLOfarm
    solution d / infusion 
    GROTEKS, LLC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    Composition per ml:

    Active substance: aminocaproic acid - 50 mg; Excipients: sodium chloride - 9 mg, water for injection - up to 1 ml.

    Theoretical osmolarity is 689 mOsmol / l.

    Description:colorless transparent liquid.
    Pharmacotherapeutic group:hemostatic agent, inhibitor of fibrinolysis.
    ATX: & nbsp

    B.02.A.A.01   Aminocaproic acid

    Pharmacodynamics:

    The hemostatic agent inhibits the conversion of the fibrinolysin to the fibrinolysin, apparently due to inhibition of the activator of this process, and also has a direct inhibitory effect on fibrinolysin; inhibits the activating action of streptokinase, urokinase and tissue kinases on fibrinolysis, neutralizes the effects of kallikrein, trypsin and hyaluronidase, reduces the permeability of capillaries. Has anti-allergic activity, improves the antitoxic function of the liver.

    Pharmacokinetics:

    The drug is quickly excreted by the kidneys - 40% -60% of the administered amount after 4 hours is excreted unchanged in the urine. If the excretory function of the kidneys is violated, the concentration of aminocaproic acid in blood increases significantly.

    Indications:

    Bleeding (hyperfibrinolysis, hypo- and afibrinogenemia). Bleeding during surgical interventions on organs,rich in fibrinolysis activators and pathological conditions accompanied by increased fibrinolytic activity of the blood (for neurosurgical, intracavitary, thoracic, gynecological and urological operations, including prostate, lung, pancreas, tonsillectomy, after dental interventions, in operations using the apparatus artificial circulation).

    Diseases of internal organs with hemorrhagic syndrome. Premature detachment of the placenta, prolonged retention in the uterine cavity of the dead fetus, complicated abortion.

    Prevention of secondary hypofibrinogenemia in massive transfusions of canned blood.

    Contraindications:

    Hypersensitivity to the drug, a tendency to thrombosis and thromboembolic diseases, hypercoagulation (thrombus formation, thromboembolism), coagulopathy due to diffuse intravascular coagulation, kidney disease with impaired excretory function, hematuria, pregnancy, cerebral circulation disorders.

    Carefully:

    Arterial hypotension, valvular heart disease, hematuria, including unidentified etiology, liver failure.

    Pregnancy and lactation:

    The use of the drug during pregnancy is contraindicated.

    During lactation, the use of the drug is possible if the intended benefit to the mother exceeds the potential risk to the child.

    Dosing and Administration:

    Intravenously, drip.

    For acute bleeding, 4-5 g diluted in 250 ml of 0.9% sodium chloride solution are injected for 1 hour, then if necessary 1 g (50 ml) every hour for 8 hours or until the bleeding is completely stopped. With repeated bleeding, infusions are repeated every 4 hours.

    Children - at the rate of 100 mg / kg body weight in the first hour, then 33 mg / kg / h, the maximum daily dose of 18 g / m 2, the body surface. The daily dose for adults is 5-30 g. The daily dose for children under 1 year is 3 g; 2-6 years - 3-6 g; 7-10 years - 6-9 g; 11-18 years - 5-30 g. With acute blood loss: children under 1 year of age - 6 g; 2-4 years - 6-9 g; 5-8 years - 9-12 g; 9-10 years - 18 g; 11-18 years - 5-30 g. Duration of treatment - 3-14 days.

    Side effects:

    Dizziness, tinnitus, headache, nausea, diarrhea, upper respiratory tract inflammation, nasal congestion, skin rash, orthostatic arterial hypotension, convulsions, acute renal failure, subendocardial hemorrhage, rhabdomyolysis, lowering of blood pressure, myoglobinuria.

    Interaction:

    Decreased efficacy with simultaneous use of anticoagulants direct and indirect action, antiplatelet agents.

    Special instructions:

    The purpose of the drug requires checking the fibrinolytic activity of blood and the concentration of fibrinogen in the blood. It is necessary to control the coagulogram, especially in ischemic heart disease, after myocardial infarction, in pathological processes in the liver.

    Effect on the ability to drive transp. cf. and fur:

    There are no data on the effect of the drug when performing work that requires increased attention, high speed of mental and motor reactions (driving vehicles, controlling mechanisms, devices and other potentially hazardous activities).

    Form release / dosage:

    Solution for infusions 50 mg / ml.

    Packaging:

    100 ml in bottles of high-density polyethylene of low density.

    The polyethylene bottle together with the instruction for use is put in a bag of film and welded (holes in the welded seam for the release of air from the polyethylene bag are allowed).

    Vials in bags are placed in a box of corrugated cardboard.

    Storage conditions:

    In the dark place at a temperature of 0 to 20 ° C. Do not freeze.

    Keep out of the reach of children.

    Shelf life:Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N002586 / 01
    Date of registration:18.07.2008
    The owner of the registration certificate:MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.08.2011
    Illustrated instructions
      Instructions
      Up